Novus Biologicals Announces Acquisition of Imgenex

For immediate release

Novus Biologicals Announces Acquisition of Imgenex

Acquisition further strengthens Novus™ catalog of more than 200,000 Life Sciences products

Littleton, Colo.  Oct. 30, 2013 “ Novus Biologicals, a leading developer and marketer of Life Sciences products, is pleased to announce its acquisition of San Diego-based Imgenex Corporation. Imgenex is a provider of specialized reagents for Life Science research with particular strength in the areas of Innate and Adaptive Immunity, Apoptosis and Cancer. The acquisition of Imgenex expands Novus Biologicals™ product catalog, which includes more than 200,000 unique Life Sciences products. Novus is a portfolio company of growth equity investor Mainsail Partners, which invested additional equity to support the companys acquisition strategy.

"We are extremely excited about the addition of Imgenex to Novus", said Karen Padgett, CEO of Novus. "They have long been known as a leader in providing high-quality products for studying Toll-like Receptor (TLRs) and Innate Immunity. I look forward to welcoming the Imgenex employees to the Novus team. The addition of their knowledge and expertise will further enable us to provide the quality of products and service our customers have come to expect."

Imgenex is well known for its extensive line of products used to study TLRs. This class of proteins plays a key role in the innate immune system, as well as the digestive system. Imgenex™ products and expertise also extend to other areas of research, including cancer, apoptosis, signaling pathways, cellular aging, metabolic and infectious diseases. Imgenex products are already available on Novus™ website through a previous distribution partnership.

"The acquisition of Imgenex represents the first step in our strategy of expanding the Novus catalog of proprietary products through acquisition," added Dave Eansor, Senior Vice President of Corporate Development at Novus. "This acquisition further supports Novus Biologicals™ core mission of accelerating scientific discovery by developing and marketing unique products for Life Sciences. We are excited to work alongside Mainsail Partners to continue to build a market-leading platform in the Life Sciences research market."

Users of Imgenex products will also benefit from Novus™ powerful website and technical support network. Novus currently has offices in Europe and Canada, as well as an extensive network of global distribution partners. The company has been on the Inc. 5000 list of fastest growing privately held companies in the U.S. for seven consecutive years.

About Novus Biologicals
Novus Biologicals is a biotechnology company whose mission is to accelerate scientific discovery by developing and marketing unique products at the forefront of science. Novus Biologicals provides primary antibodies, secondary antibodies, conjugated antibodies, proteins, peptides, isotype and loading controls, RNAi, lysates, stem cell lines and antibody labeling kits to the bioscience community. All of Novus' products are 100% guaranteed to work in the species and applications listed on the datasheet. By serving niche and emerging markets, Novus Biologicals strives to form ongoing partnerships with leading researchers. For more information, visit

About Mainsail Partners
Mainsail Partners is a leading growth equity firm that invests in growing, bootstrapped businesses and helps build them into industry-leading companies. Mainsail leverages a dedicated team of experienced operators and a powerful network to accelerate growth at the firms portfolio companies. The San Francisco-based firm has raised nearly $400 million in committed capital to back outstanding entrepreneurs. Mainsail™ recent investments include Netchemia, a K-12 Talent Management Suite, and Zen Planner, a leader in cloud-based business management software for the health and fitness industry. For more information, visit

Additional information available at:

Dave Eansor, Senior VP Corporate Development
Novus Biologicals, LLC

Release Date: 
Wednesday, October 30, 2013 - 06:00